Living dossier · Competitive landscape

Amylin receptor in Obesity

Primary identifiers: 8
Sponsors tracked: 5
Evidence types: 2 of 3
Last refreshed: 2026-07-28 · monthly

MightyRayn panel synthesis

OmniRayn’s reading of this landscape — our interpretation, not a registry fact

Amylin is the field's answer to the question the incretin landscape leaves open: how to keep reducing weight without simply pushing incretin dose and paying for it in tolerability. The registry shows two distinct bets running in parallel — amylin as a partner bolted onto an incretin backbone, and amylin as a standalone agonist — and the literature treats this as a class rather than a single molecule. Note the concentration: nearly every citable programme here belongs to two large developers, so the open competitive question is less whether amylin works than whether anyone outside that pair establishes a position.

Programs and primary evidence

Sponsor	Asset	Phase	Mechanism	Primary source
Novo Nordisk	CagriSema (cagrilintide + semaglutide)	3	amylin analogue co-formulated with a GLP-1 receptor agonist	NCT05567796 — Phase 3 of cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly in overweight or obesity
Novo Nordisk	CagriSema	3	amylin analogue plus GLP-1 receptor agonist	NCT07011667 — Weight management and long-term weight maintenance in participants with obesity
Novo Nordisk	CagriSema (long-term)	3	amylin analogue plus GLP-1 receptor agonist	NCT06780449 — Long-term efficacy and safety versus placebo in participants with obesity
Zealand Pharma	Petrelintide	2	long-acting amylin analogue as monotherapy	NCT06926842 — Phase 2 of once-weekly petrelintide versus placebo in overweight or obesity with type 2 diabetes
Eli Lilly and Company	Eloralintide	3	selective amylin receptor agonist as monotherapy	NCT07321886 — Phase 3 of once-weekly eloralintide in obesity or overweight without type 2 diabetes
Eli Lilly and Company	Eloralintide (T2D)	3	selective amylin receptor agonist	NCT07282600 — Phase 3 of once-weekly eloralintide in obesity or overweight with type 2 diabetes
Aston University / Ulster University	review	—	amylin and calcitonin receptor pharmacology	10.1016/j.peptides.2026.171480 — Long-acting amylin-related peptides for obesity and type 2 diabetes; identifies cagrilintide, eloralintide and petrelintide as amylin analogues
University College Dublin	review	—	selective amylin receptor and dual amylin/calcitonin receptor agonism	10.1111/dom.71074 — Review of amylin-based therapies in clinical development for obesity, standalone and in combination

Method and limits

Programs are enumerated from primary registries (ClinicalTrials.gov, PubMed). A program appears here only if a primary record links this target to this indication as a therapeutic hypothesis — associations and risk markers are excluded by design.
Every claim above carries the identifier it rests on. We report what the record states; we do not assert efficacy, and computational findings are pending wet-lab confirmation.
Absence is not evidence of absence: unregistered, non-US and stealth-stage programs are not visible to these sources.
This page refreshes monthly (no net-new primary entity in 14 days). Mechanism classifications are our reading of the public record and may be revised.

Want the analysis behind this landscape?

The public page is the map. The full dossier adds differentiation analysis, kill-tests and the whitespace read for this target — the parts we do not publish.

Request the full dossier All landscapes